RT Journal Article
SR Electronic
T1 A randomized, double-blind, placebo-controlled decentralized trial to assess sleep, health outcomes, and overall well-being in healthy adults reporting disturbed sleep, taking a melatonin-free supplement
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.02.23292135
DO 10.1101/2023.07.02.23292135
A1 Kolobaric, Antonija
A1 Hewlings, Susan J
A1 Bryant, Corey
A1 Colwell, Chris
A1 D’Adamo, Chris
A1 Rosner, Bernard
A1 Chen, Jeff
A1 Pauli, Emily K
YR 2023
UL http://medrxiv.org/content/early/2023/07/11/2023.07.02.23292135.abstract
AB Inadequate sleep is a global health concern. Sleep is multidimensional and complex; new multi-ingredient agents are needed. This study assessed the comparative effects of two multi-ingredient supplements on sleep relative to placebo. Adults (N=620) seeking better sleep were randomly assigned to receive 1 of 3 study products (Sleep A, Sleep B or placebo) for 4 weeks. Both active products contained federally legal hemp-derived cannabinoids, botanical oils, GABA and L-theanine. Sleep disturbance was assessed at baseline and weekly using NIH’s Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep Disturbance SF 8A survey. Anxiety, stress, pain, and well-being were assessed using validated measures at baseline and weekly. A linear mixed-effects regression model was used to assess the change in health outcome score between active product groups and the placebo. There was a significant difference in sleep disturbance, anxiety, stress, and well-being between Sleep A and placebo. There was no significant difference in any health parameter between Sleep B and placebo. Side effects were mild or moderate. There were no significant differences in the frequency of side effects between the study groups. A botanical blend containing a low concentration of THC improved sleep disturbance, anxiety, stress, and well-being in healthy individuals that reported better sleep as a primary health concern.Competing Interest StatementAntonija Kolobaric, Susan Hewlings, Corey Bryant, Jeff Chen and Emily Pauli are employees of Radicle Science, the research organization contracted to conduct this trial.Clinical TrialNCT05511818Funding StatementThis study was funded by MDbio - The Doctors BrandAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Radicle Rest: A randomized, blinded, controlled, direct-to-consumer study assessing the impact of plant derived cannabinoids on sleep and overall health outcomes was registered on ClinicalTrials.gov (NCT05511818) and reviewed and approved by Sterling Independent Review Board (SIRB) (10147).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors